# Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

> **NCT01673178** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 107 (actual)

## Conditions studied

- Diabetes Melliuts, Type 2

## Interventions

- **OTHER:** Placebo
- **DRUG:** 25 mg PF-05231023
- **DRUG:** 50 mg PF-05231023
- **DRUG:** 100 mg PF-05231023
- **DRUG:** 150 mg PF-05231023

## Key facts

- **NCT ID:** NCT01673178
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-08
- **Final completion:** 2013-09
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2015-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673178, "Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01673178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*